Clinical Trials Browser

INDUSTRY × Neuroblastoma × Clear all

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT06395103 2026-03-11

MK-9999-01A

Phase 1/2 Recruiting

90 enrolled

CNSLymphoidSarcoma

Burkitt Lymphoma, Neuroblastoma, Sarcoma, Ewing, Lymphoma, Large B-Cell, Diffuse

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Phase 2 Completed

20 enrolled

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Phase 1/2 Completed

47 enrolled 36 charts

CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Clinical Trials

CLOVER-2

MK-9999-01A

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Pediatric Long-Term Follow-up and Rollover Study

SPEARHEAD-3 Pediatric Study

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

STARTRK-NG

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Racotumomab in Patients With High-risk Neuroblastoma

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

PIVOT IO 020

Phase 1 Study of BCD-245 in Subjects With Neuroblastoma

Expanded Access Protocol Using 131I-MIBG

OPTIMUM

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

My-CRA

Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients